22/02/2017
MINORYX THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM THE US FDA FOR ITS LEAD CANDIDATE MIN- 102
MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the EMA. [...]
